Otonomy, Inc. (NASDAQ:OTIC) saw an uptick in trading volume on Thursday following a better than expected earnings announcement. 27,930,008 shares were traded during mid-day trading, an increase of 4,555% from the previous session’s volume of 600,004 shares.The stock last traded at $5.13 and had previously closed at $5.13.
The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.84) by $0.15. The company had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $0.43 million. Otonomy had a negative net margin of 7,899.03% and a negative return on equity of 57.33%. The firm’s revenue was down 12.8% compared to the same quarter last year.
Several research firms recently weighed in on OTIC. ValuEngine cut shares of Otonomy from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Cowen and Company reaffirmed an “outperform” rating and set a $9.00 target price (down from $55.00) on shares of Otonomy in a research note on Thursday, August 31st. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $15.00 target price (down from $45.00) on shares of Otonomy in a research note on Thursday, August 31st. Piper Jaffray Companies cut shares of Otonomy from an “overweight” rating to a “neutral” rating and cut their target price for the company from $32.00 to $8.00 in a research note on Wednesday, August 30th. Finally, J P Morgan Chase & Co cut shares of Otonomy from an “overweight” rating to a “neutral” rating and cut their target price for the company from $28.00 to $8.00 in a research note on Wednesday, August 30th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $10.00.
Several large investors have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd purchased a new position in shares of Otonomy in the 3rd quarter worth $263,000. Bank of New York Mellon Corp grew its stake in shares of Otonomy by 72.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 596,784 shares of the biopharmaceutical company’s stock worth $1,939,000 after buying an additional 249,845 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Otonomy in the 3rd quarter worth $126,000. Lakeview Capital Partners LLC purchased a new position in shares of Otonomy in the 3rd quarter worth $120,000. Finally, California State Teachers Retirement System grew its stake in shares of Otonomy by 5.7% in the 2nd quarter. California State Teachers Retirement System now owns 49,993 shares of the biopharmaceutical company’s stock worth $942,000 after buying an additional 2,700 shares in the last quarter. 89.03% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This piece was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://stocknewstimes.com/2017/11/11/otonomy-inc-otic-sees-unusually-high-trading-volume-following-better-than-expected-earnings.html.
Otonomy Company Profile
Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.
Receive News & Ratings for Otonomy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.